Roche Chief Executive Dr. Thomas Schinecker announced as President of global pharmaceutical industry trade association, IFPMA
Dr Thomas Schinecker & Dr David Reddy
The global pharmaceutical industry trade body, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), has announced that Dr. Thomas Schinecker, Chief Executive Officer, Roche Group, will take up the post as President of the association from 1 January 2025.
Thomas, who acted as IFPMA Vice-President over the past two years, will be joined by Rob Davis, Chief Executive of MSD (known as Merck & Co., Inc in the United States and Canada), who will serve as a newly appointed Vice-President, alongside Dr. Sunao Manabe, Executive Chairperson and CEO of Daiichi Sankyo, who has extended his existing term as Vice-President.
The appointment of IFPMA’s new CEO Leadership Team comes as current President, Dr Albert Bourla and Chairman and Chief Executive Officer of Pfizer, completes his term.
Commenting on his appointment, Dr Thomas Schinecker said:
“I’m honored to have been appointed as the new President of IFPMA. It has been a pleasure to work as part of the IFPMA CEO Leadership Team over the past 18 months and I want to thank Albert Bourla for his tremendous service and partnership during his term as President.
“I am excited about the potential of medical innovation to transform healthcare and meet the challenges we face today. As we work toward IFPMA’s vision of turning scientific progress into the next generation of life-saving medicines and vaccines, I am confident we can build a healthier future for people everywhere, together.
“Our industry will stay at the forefront — championing forward-thinking policies, impactful partnerships, and pioneering innovations. I look forward to working with the IFPMA team to achieve meaningful progress toward these goals.”
Welcoming the new CEO leadership team, IFPMA Director General Dr David Reddy said:
“I am delighted to welcome the new IFPMA CEO Leadership Team and look forward to working closely together as we enter a new period of incredible scientific innovation and importance for global health.
“The breadth of experience they bring will be invaluable to IFPMA as we continue to deliver on our priorities on behalf of our members.
“I also want to thank Albert Bourla for his outstanding contribution in providing leadership to IFPMA and to our industry, and for the generous support and guidance he provided me over the last eight months in my new role as Director General.”
Commenting on his tenure as IFPMA President, Dr Albert Bourla said:
“It has been an honor to lead IFPMA. Our industry is in the business of pushing the limits of scientific knowledge, and this organization’s leadership is essential at a time when the need for innovative medicines and vaccines continues to grow.
“IFPMA does a tremendous job in bringing together partners to champion innovation and provide the support we need for more breakthrough advances, and I am proud of the progress we have achieved together. I want to thank Thomas and Manabe-san for their partnership over the past two years as Vice Presidents, and I wish the whole IFPMA the very best for the next chapter.”
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
